Recruiting
Phase 2

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Sponsor:

Akeso

Code:

NCT06196203

Conditions

Higher-risk Myelodysplastic Syndromes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AK117

Placebo

Azacitidine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Akeso on 2025-03-25.